Hybrid Closed-Loop Insulin Delivery System

 The most promising breakthrough in healthcare innovation technology will be a hybrid insulin delivery system commonly known as an artificial pancreas. This is the next step in developing a fully automated delivery system.

This innovation health system is designed for the treatment of type 1 diabetes. An automatic insulin delivery system that connects a constant glucose meter to an insulin pump, removing the necessity for diabetic people to self-test and monitor insulin levels. Studies have shown that this system stabilizes blood sugar levels and lowers A1C levels by an additional 0.5%.

One example is Medtronic, which joined the group in 2018 when it received FDA approval for its MiniMed 670G AI pancreas hybrid closed loop system. While this system is not a separate artificial pancreas that requires carbohydrate intake and a baseline blood sample, it is an important step in developing a fully functional closed-loop solution.